<SEC-DOCUMENT>0001193125-15-387722.txt : 20151125
<SEC-HEADER>0001193125-15-387722.hdr.sgml : 20151125
<ACCEPTANCE-DATETIME>20151125062430
ACCESSION NUMBER:		0001193125-15-387722
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20151125
FILED AS OF DATE:		20151125
DATE AS OF CHANGE:		20151125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		151254407

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d75832d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 25 November 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g75832tx03.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">424 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting CEO</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24&nbsp;November 2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN ENGAGES CONTRACT RESEARCH ORGANISATION TO CONDUCT CANTRIXIL PHASE 1 CLINICAL TRIAL</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>Novogen engages Novotech as CRO for upcoming Phase 1 clinical study</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>Cantrixil
Phase 1 clinical trial to be conducted in patients with refractory/recurrent peritoneal malignancies with malignant ascites, including ovarian cancer</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, November&nbsp;24, 2015 &#150; </B>US-Australian drug discovery company, Novogen Limited (ASX:NRT: NASDAQ: NVGN), announced today that it has engaged
Novotech as the Contract Research Organisation (CRO) to conduct its Phase 1 clinical study for the drug candidate, Cantrixil, which will commence in 2016.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This first-in-human study will investigate the safety and feasibility of Cantrixil administered via the intraperitoneal route for patients with refractory
/recurrent peritoneal malignancies with malignant ascites.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to
Novogen&#146;s Clinical and Regulatory Affairs Manager, Kimberley Lilischkis, PhD, the Cantrixil Phase 1 study will be weighted towards ovarian cancer patients with the selection of a gynecological oncology site.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#147;However, patients with other cancer types will also be eligible to enrol in this
first study since early preclinical data suggests the drug candidate may benefit patients with a range of cancer types,&#148; Dr Lilischkis said.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Patients with malignant ascites have been chosen
because ethically this patient group stands to receive the most benefit and face the least risk from the insertion of a peritoneal port or catheter, which can be used for drug administration but also for the on-going drainage of malignant
ascites.&#148;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr Lilischkis said Novogen was continuing to progress Cantrixil
through the necessary preclinical regulatory requirements and safety evaluations and was on track to complete the &#145;in-life&#146; phase of the toxicity studies by the end of 2015. The Company expected to receive the final report in early 2016
once a comprehensive pathology review was completed.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g75832footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g75832header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting CEO, Iain Ross said the appointment of Novotech was a key milestone in progressing Novogen&#146;s
first oncology drug candidate, Cantrixil, to the clinic. &#147;Novogen is confident that Novotech will add significant value to the clinical trial program bringing their standard of excellence to the development of this promising drug
candidate,&#148; Mr Ross said. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novotech is a prominent Australian-based CRO with extensive background in oncology drug development and a broad range of
clinical trial outsourcing services. Novotech has well-established working relationships with the Australian sites and KOLs working with Novogen on this study. This CRO has world-class electronic data and trial management systems that will support
the data management, monitoring and safety reporting activities for this study. Novotech is the only Australian-based CRO that has a Quality Assurance system with ISO9001:2008 accreditation and has a superb track record in managing early phase
oncology studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#146;re delighted to be working with Novogen on this important study. The development of Cantrixil has the potential to add an
important new tool in the fight against cancer, and we are looking forward to leveraging our previous experience in all phases of oncology drug development to the management of this program,&#148; CEO of Novotech, Alek Safarian, said. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Cantrixil drug candidate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The candidate
Cantrixil drug product is cyclodextrin-based containing the active ingredient, TRXE-002-1. The Company anticipates that if approved the drug product would be used as an intra-cavity chemotherapy to be injected directly into the peritoneal cavity.
The aim of intraperitoneal administration is to achieve high localized drug levels within the peritoneal cavity and attenuate the spread of resident tumor initiator cells. The target indication sought for Cantrixil is early-stage cancers of the
abdominal cavity (eg. ovarian, uterine, colorectal and gastric carcinomas) with Cantrixil being used as an adjuvant first-line therapy. On completion of the requisite safety studies, Cantrixil will enter the clinic in late-stage patients with
abdominal cancers including ovarian cancer. The active pharmaceutical ingredient, TRXE-002, has pan anti-cancer activity resulting in caspase-dependent apoptosis via c-Jun activation and pERK downregulation. The actual drug target remains
unidentified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a
public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen Group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug
technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)] yielding drug candidates that are first-in-class with potential application across a range of degenerative diseases. Given the encouraging data from <I>in vitro</I> and
<I>in vivo</I> preclinical proof-of-concept studies in the field of oncology, the Company&#146;s immediate focus is to undertake the respective toxicology programs. The target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine
Glioma (DIPG) for Trilexium. While the initial target pediatric indication for Anisina has been identified as neuroblastoma, Novogen is yet to identify the adult indication and is intending to open an all-comers Phase 1 trial initially based on its
preclinical studies. For more information, please visit <U>www.novogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g75832footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g75832header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Director, Novogen Group
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com</U> / Ph: +61 (0)&nbsp;2 9472 4109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release
contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such
words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148;
&#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#146;s drug development program, including, but not limited to, Cantrixil, and any other statements that are not
historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing
of the Company&#146;s drug components, including, but not limited to, Cantrixil, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s
drug compounds, including, but not limited to, Cantrixil, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the
intellectual property relating to Cantrixil, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements
are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those
forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g75832footer.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g75832footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g75832footer.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ / +& P$1  (1 0,1 ?_$ -0  0 !! ,! 0
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M0#?+STJY\_+Y2"J&^7GI5SY^7RDJ@-\O/2KGS\OE('LWEM=YT+"(R7N;&S8
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MX/ 0'3UCF'IUY\YG\M /6.8>G7GSF?RT ]8YAZ=>?.9_+0#UCF'IUY\YG\M
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M]A/2-;>X2@,2_)[QI.$-EYL! !%/OB""@+*2VGB_*1/C/,X$'KZ 1I0%! $
M0! $ 0! $ 0! $ 0! $!RL258M>0'9KBQS7M<6O8X/8YI(<U[*EK@1I!:=2A
M2LS2JZ4-[+E&[%Q]Y25.T]L6Q<ZUM7.-7.M8'.)TESC$TN<3RN)5+?A+6GY3
MZ;BW)SQ8\7WJ%8:>CK0['+6N=H:USCS-:YQ/>!H@+^'*[R4!QBV;3JVK@PGJ
M!J3WD!D8,D <#<35%/%B;0Z1J+G'GZ$!G&-;&QL<;0QC10-: !3X22-: [(
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M#WD 0! $ _G'OH=+/W8]I[8M/U6U_NEM_8QKS;^_<[&?2<7^7CYBNN9)" (
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MDEV2::]F\B%O<8M7DY,YK6W'R+86%KDF):>EQC--5VI,@&QAMR66\,4#&ND
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M69WK_P"%I\QHK-_W_P"^LW;<MAM?DO4OJK<O]_OWZ72FO$K%_E='I]XH+_\
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I%6'>*NV&\8M%-EBPXM%*TT=_D0$J;CPMVGCX6XM6N@KJT(#E $!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g75832header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g75832header.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 00+& P$1  (1 0,1 ?_$ ,(  0 !! ,! 0
M       % 00&!P(#" D* 0$  @,! 0$              00" P4&!P@0  $#
M P$$!@4%"@L&!P    $  @,1! 42(3%1!D%A<9$3!X&AL2)2,D)R%#31@I(S
M0W.S%34(\,%BHK(C8W2T=3;API,D1+549"46)G8G$0 " 0," P<!!@0% P4
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M:8;-+-/(Z:>:2:5YJ^25[I)''BY[W.<2K%B,HR=4UH<IU<W.?U'N=2LDA $
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M! $ 0%1M(0$9=7DL,KHXPP:=FIS=9-1MX4WH"/DN)96Z7O<1TBNP[:C9391
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M,C);P>X#6^O65G*=VYY[K3;X'-6%BXDG:PXR2[=/N)(+%EJRFDZJA50;@@"
M( @" (#HN+:VNHW0W5O%<PNWQ3,;)&>LL>'-)HMT&E'7<U7K<+T?;O)NUW&#
MY+RRY.R6HC&FPE=^5QLS[<CIV1$O@H2*_(6^.9DVER6FN1' R?CG2\MOVH2C
M-]KT-?Y/R2?1SL/GNR+)6SJ]GCVYH7'CHHM\>I7N7]2CD<:_\)5I<^-->\:]
MR7EESKC*G]6F_BH3XN.?'=5 XPC3.'=6E;XYRE&LFDS@970NL8[;N5N1X15?
MP,'N;:]LI#%=PW%K(#31<V[X'5X:9&M-:JW"XIQ4Z[G(G8OV_JPG!]Z:_$Z*
MR 5+B!NKI%*\%FDWL:4TW1/4SGRWY(N_,;G#&\IVV2AQ;[]EW/)?3P/N&PP6
M5N^XF+8(RQTLCFMHT:FBIJ315>H7)XUCW4G2AV^@](N=:ZC' QY)3EO7L[SW
M-R]^Z5Y?8T1OSN4S_,LP'OQOGCQ-BZH&IH@L0ZXTU_MZE><N];RW!>VU2FA]
MFP?[6='Q77,D\NYVQEI!/M2?:N'<;TY<\N>1>42UW+G*N&Q<K?\ J8K427I-
M*:C?3NENJD;_ 'U0OYF7E1Y922T/<=-^/=%Z4T\+#MQ:2TYM%W+N,Q[-W0JF
MJT>YV7OLEW<.XS*VV6]N/[",_P QOW57>Y?6R\"[CEDB=JB>^.F[0[3VU-#5
M027\>6NF4#RV4#?J&EQV?&VA0$BS)!]M-.(2'0^'5FO8[Q':11U-E$!*( @"
M ( @" ( @" ( @" @,]S/A^6X&S9.YT/DKX%K$WQ;FX(%3X<0+?= &UQ(:.*
ML6;$[DJ4T*>7G8^$JWWKPHW^!JS(><;R7-Q6%:T;FS9"XU$;O>\"W 'H+_2K
ML,'S>=>4\_?^1N+_ $()Q^[\3!\AYA<V9&K791UG&=ACQ\;+04X&1H=,1]\K
M$,2U;?,HU9Q;W5\^Y)SA)KNJ8=/--<R&6YFFN)3ODGEDG>>UTI<5OA"$76,%
M%E"5R_=ES7I-K@8CF?M5:4!CCILH-FJM.C95;""(0! $ 0! $ 0! $ 0! $
M0! * [P#U$5_B5:[;G*=8K0R5R451;$A997)XUP=C\A>6=#6EO<2QM)ZV!VD
MCJI1(V$U6>DC=:RK]I\UN33,XQ_FES5:4;<S6N3C;2C;R ,D(Z?ZZV\)VWK!
MXJM<PG*;:6ATL?K^99=;BY_%F=8SS?QD[F,RN,NK$DT=+:R,NX6GBYKA%-H[
M XJI<PZ3:.S9^4PNOEOVU;CQW_"IM:SO+3(VT5[87$5U:3MU131.U-=\33TM
M>T["#M"K3@[6DMCOXUV&7:5ZP^:#[=OQH7"P3355L; I 0! 3.#^UN_,N/8
MYAV\*@(#)T 0! $ 0! $ 0! $ 0! 5&_T'V% 0-]]IE[1[$!:( @" (#B7-;
MO(]OJ&U =1G;P)Z^* X>,_4*&@U;*;^K:@=>5I=J-*W-O!#?7SXH(HW/O+AS
MG,8T.<YTSW.).^I=M71AZ$>7N8MKWY7%ZGN=9->@=HZ>U290M1MNJ[2BDVEO
M>_8;W^Z77Z!R+U(J9GTGX'G!GR1V#V!=./I1X.7UI^)S4D! $ 0! $ 0! $
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M 0%O>?8;P?\ E+G]"]%N5<Q4QY3[$CSBT4:.P>P+I1]*/ O6<IK9LY+(! $
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MQ[31S7-(WAS2"/015 <4 0! $ 0! $ 0! <FM<\T8USCP:"3ZD!>18V^D%?
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M9NB-+C./KBXG%;#$( @.+VLD&E[&/;P<T.'KJ15 6+\79/U 1B'5M)CJ-H'
MUWH"-FPA&V"8$<)6T/>TE 1\N-O(M\)>.,9#_4/>'<@+)S7,=I>"UW!PH>XH
M"E#2O0.FH'M0%6M<\Z6-<YW!H+CW"J OXL7>2"OA^'4>[XATU[=Y ]" OHL&
M[\O.*<(F$^BKR-H[$!(,Q5DRE8O$IN\1Q<*\:;!ZD!?L8R-NAC&-;P#6CKZ!
M7>@.0%!1 >C/*+_3E[_FTO\ AK5<;JGU('M/C_T/L_,VHJ=SUOQ/0K8+ D(
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M-]SB@.N:&&Y88[F&&XC(H67$3)F4.\%LC7"A649.,E(PG;M27ZD4UX(Q"_\
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MG:3MV+RUR:N3<HNJ;/M73L"/3+'MVW6;6K\3)U@7(I15%L$)" ( @" ( @"
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MDWR_0$!U( @" ( @" ( @" [/R,O\.A#&6QC+_G=O\:VQ*DO6SK68" ( @"
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950! $ 0! $ 0! $ 0%S!N=VCV(#O0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g75832tx03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g75832tx03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C +& P$1  (1 0,1 ?_$ -4  0 !! ,! 0
M       % 08'" (#! D* 0$  04! 0$!            !0$" P0&!P@)"A
M 0,# @,$! <+!@L%"0   0(#!  %!A$'(3$202(3"%%AH11Q@;$R8B,5D=%"
M4G(S-'2U%@GPLF-SLS;!HL)#4R2T)347-_&"DF1VX9.C1$55E1@*$0 " 0,"
M @@#! @""@ '     0(1 P0A!3$205%A<2(R$P8S% >!D;$CH<%"4G(T%0CP
M8M'A\<)#<R0U%C:"DK)31"47_]H # ,!  (1 Q$ /P#]Q% * 4 H!0"@% *
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M"#V&L%R#A*A.VIV[D%.UK 587B@% * 4 H!0"@% 7A:?^'M_UCG\Y5 2% *
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M)/IJ.N6;EA?F)QB=E8S[&7%7(27/)5:Z57H)OI/HK&I*7 V:HI52HH!0"@%
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M>?GEWG"JE10%M9I_=F9_6QO]J9J^WYR)W7X+,'CD*DGQ.*M^7[_Q*U0O% *
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MML-NB=;@0# EK44H2?G>[/=Y<<^H:I/:*U[V/;G\/3O)?;]XSL.D9M."ZO\
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M4T?!4K7AS;)]?-21QXZ4!;S\5^,KI>;4DZ\#S0H=A"AZ?0=#0'FH!0"@% *
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M"T\T4]6I!YC@:XZ_9^7DXOH/=]CW2UNVUK/LZVZT[ZO]7 RHS&8CIZ6D=)T
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M@GF* MV7:W6R5LZNHT)Z>(6C0<B5?.  H")*2"1H?C!U^Y0%* I0"@% * 4
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MEH'I4H:?..I/IK9A:C!4XG+O*NY59<S4*TH159*)<"V,5%416A44 H!0"@%
M* 4 H!0"@% * 4 H!0&OV^OS<9_*NOR0*E=K\\NXX'WM\3$_B9@"I,X7I?\
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M(=+BU^[\"T)UHDPP5CZ]D#J+C8.J4_3;XJ3IVGB/74@K\&Z(BLC$N8SH_$1
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M.O1(?)6GFA**@\K?<K,C*$8<MEOBM#T3VO\ 3C;MCNQS-RNVK^51/@G&,O\
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
